[{"data":1,"prerenderedAt":241},["ShallowReactive",2],{"$fvc0da54i8kfz":3},{"schema":4,"slug":5,"series":6,"series_slug":7,"name":8,"year":9,"therapeutic_area":10,"generated_at":11,"counts":12,"top_targets":21,"top_modalities":56,"top_diseases":82,"top_companies":116,"key_results":148,"trends":207,"previous_editions":216,"comparison":220,"highlighted_classes":240},1,"asn-2026","ASN","asn","ASN Kidney Week 2026",2026,"Nephrology","2026-11-05T22:19:09Z",{"abstracts":13,"drug_linked":14,"companies":15,"by_phase":16},4352,1667,240,{"Phase 1":17,"Phase 1\u002F2":4,"Phase 2":18,"Phase 4":4,"Phase 2\u002F3":19,"Phase 3":20},23,34,5,52,[22,26,30,34,37,40,44,47,50,53],{"name":23,"count":24,"share":25},"CD20",142,9,{"name":27,"count":28,"share":29},"GR",117,7,{"name":31,"count":32,"share":33},"C5",54,3,{"name":35,"count":36,"share":33},"SGLT2",51,{"name":38,"count":39,"share":33},"MR",49,{"name":41,"count":42,"share":43},"AGTR1",39,2,{"name":45,"count":46,"share":43},"GLP1R",37,{"name":48,"count":49,"share":43},"CD38",35,{"name":51,"count":52,"share":43},"AVPR2",31,{"name":54,"count":55,"share":43},"EDNRA",29,[57,61,65,68,72,75,77,79],{"name":58,"count":59,"share":60},"Small molecules",1055,63,{"name":62,"count":63,"share":64},"Monoclonal antibodies",367,22,{"name":66,"count":67,"share":29},"Peptides",111,{"name":69,"count":70,"share":71},"Non-antibody therapeutic proteins",64,4,{"name":73,"count":74,"share":43},"Oligonucleotide and RNA therapeutics",28,{"name":76,"count":17,"share":4},"Carbohydrate, lipid and polymer therapeutics",{"name":78,"count":64,"share":4},"Blood, tissue and cell-derived products",{"name":80,"count":81,"share":4},"Cell therapies",20,[83,87,90,94,98,100,103,107,110,113],{"name":84,"count":85,"share":86},"acute kidney failure (AKF)",434,26,{"name":88,"count":89,"share":86},"chronic kidney disease (CKD)",432,{"name":91,"count":92,"share":93},"end-stage kidney disease (ESKD)",177,11,{"name":95,"count":96,"share":97},"Hyper IgM syndrome type 1 (HIGM1)",172,10,{"name":99,"count":24,"share":25},"nephrosis",{"name":101,"count":102,"share":29},"hypertension (HTN)",120,{"name":104,"count":105,"share":106},"type 2 diabetes mellitus (T2DM)",105,6,{"name":108,"count":109,"share":106},"kidney allograft rejection",93,{"name":111,"count":112,"share":71},"focal segmental glomerulosclerosis (FSGS)",75,{"name":114,"count":115,"share":71},"membranous glomerulonephritis (MGN)",71,[117,121,124,127,130,133,136,139,142,145],{"name":118,"count":119,"share":120},"Genentech",131,8,{"name":122,"count":123,"share":19},"Pfizer",85,{"name":125,"count":126,"share":19},"AstraZeneca",80,{"name":128,"count":129,"share":71},"Bayer",72,{"name":131,"count":132,"share":71},"Novartis",68,{"name":134,"count":135,"share":71},"Roche",61,{"name":137,"count":138,"share":33},"Merck",58,{"name":140,"count":141,"share":33},"Alexion Pharmaceuticals",53,{"name":143,"count":144,"share":33},"Johnson & Johnson",46,{"name":146,"count":147,"share":43},"Bristol Myers Squibb",41,[149,158,165,171,178,185,192,199],{"title":150,"drug":151,"company":153,"phase":154,"disease":155,"finding":156,"url":157},"Safety and Efficacy of Inebilizumab in IgG4-Related Disease: Subgroup Analysis from MITIGATE",{"name":152,"slug":152},"inebilizumab","Amgen","Phase 3","IgG4-related disease (IgG4-RD)","The proportion of patients achieving flare-free, corticosteroid-free complete remission was higher with INEB vs PBO (57.1% vs 21.1%; odds ratio 5.08, nominal p=0.0281).","https:\u002F\u002Fwww.asn-online.org\u002Feducation\u002Fkidneyweek\u002F2026\u002Fprogram-abstract.aspx?controlId=4553812",{"title":159,"drug":160,"company":137,"phase":154,"disease":162,"finding":163,"url":164},"Enlicitide, an Oral PCSK9 Inhibitor, for Lipid Lowering: Pooled Analysis of the Phase 3 CORALreef Lipids and HeFH Trials by Baseline eGFR",{"name":161,"slug":161},"enlicitide","hypercholesterolemia","At Week 24, in enlicitide-treated pts with eGFR \u003C60, 80.5% achieved LDL-C \u003C70 mg\u002FdL (81.5% eGFR ≥60) and 74.9% achieved \u003C55 mg\u002FdL (74.7% eGFR ≥60), all significantly greater than placebo ( P \u003C0.001).","https:\u002F\u002Fwww.asn-online.org\u002Feducation\u002Fkidneyweek\u002F2026\u002Fprogram-abstract.aspx?controlId=4558380",{"title":166,"drug":167,"company":131,"phase":154,"disease":95,"finding":169,"url":170},"Atrasentan in Patients (Pts) with IgAN from East (E) Asia: Phase 3 ALIGN Final Data",{"name":168,"slug":168},"atrasentan","Fluid retention adverse events occurred in 7 (10.3%) pts on atrasentan vs 4 (5.7%) on placebo; none led to discontinuation.","https:\u002F\u002Fwww.asn-online.org\u002Feducation\u002Fkidneyweek\u002F2026\u002Fprogram-abstract.aspx?controlId=4558229",{"title":172,"drug":173,"company":175,"phase":154,"disease":111,"finding":176,"url":177},"Sparsentan (SPAR) vs. Irbesartan (IRB) in Patients (Pts) with FSGS Without Nephrotic Syndrome (NS) in the Phase 3 DUPLEX Trial",{"name":174,"slug":174},"sparsentan","Travere Therapeutics","More pts in the SPAR vs IRB arm achieved CR (20% vs 6%), UPCR \u003C0.7 g\u002Fg (43% vs 22%), and \u003C1.5 g\u002Fg (79% vs 50%); nominal P \u003C.01 for all thresholds.","https:\u002F\u002Fwww.asn-online.org\u002Feducation\u002Fkidneyweek\u002F2026\u002Fprogram-abstract.aspx?controlId=4553566",{"title":179,"drug":180,"company":131,"phase":154,"disease":95,"finding":183,"url":184},"Efficacy and Safety of Iptacopan in East Asian Patients with IgAN: Final 24-Month Results from the Phase 3 APPLAUSE-IgAN Trial",{"name":181,"slug":182},"Iptacopan","iptacopan","AE rates were similar (iptacopan: 92.2% vs PBO: 89.1%); most were mild to moderate.","https:\u002F\u002Fwww.asn-online.org\u002Feducation\u002Fkidneyweek\u002F2026\u002Fprogram-abstract.aspx?controlId=4558046",{"title":186,"drug":187,"company":189,"phase":154,"disease":95,"finding":190,"url":191},"Slowing of Kidney Function Decline to Physiological Rates with Nefecon in Patients with IgAN: A NefIgArd Subanalysis",{"name":188,"slug":188},"nefecon","Calliditas Therapeutics","Of the 182 patients in each arm of the NefIgArd trial, significantly more patients receiving nefecon (61%) than placebo (33%) experienced a reduction in eGFR loss to \u003C1 mL\u002Fmin\u002F1.73 m 2 at 9 months.","https:\u002F\u002Fwww.asn-online.org\u002Feducation\u002Fkidneyweek\u002F2026\u002Fprogram-abstract.aspx?controlId=4558073",{"title":193,"drug":194,"company":196,"phase":154,"disease":101,"finding":197,"url":198},"Blood Pressure and Albuminuria Reduction with Lorundrostat in CKD Stages 1 to 3 in the Launch-HTN Trial",{"name":195,"slug":195},"lorundrostat","Mineralys Therapeutics","Placebo-adjusted reduction in AOSBP was -12.2 mmHg and -9.6 mmHg in participants without and with CKD, respectively.","https:\u002F\u002Fwww.asn-online.org\u002Feducation\u002Fkidneyweek\u002F2026\u002Fprogram-abstract.aspx?controlId=4552575",{"title":200,"drug":201,"company":203,"phase":204,"disease":91,"finding":205,"url":206},"Effects of Lumasiran in Patients with Hyperoxalemia on Maintenance Haemodialysis",{"name":202,"slug":202},"lumasiran","Alnylam Pharmaceuticals","Phase 2","At month 6 the pooled pairwise comparison of placebo versus lumasiran was estimated at -11.32% change in plasma oxalate without significant a treatment effect (p= 0.174, 95% CI [-27.64, 5.00]).","https:\u002F\u002Fwww.asn-online.org\u002Feducation\u002Fkidneyweek\u002F2026\u002Fprogram-abstract.aspx?controlId=4556781",{"summary":208,"bullets":210},[209],"Monoclonal antibodies accounted for 22% of drug-linked abstracts, up from 17% in 2025. CD20, the most frequent target, accounted for 9% of drug-linked abstracts, up from 6% in 2025. CD38 (2%) was new to the top targets compared with 2025.",[211,212,213,214,215],"Small molecules were the most frequent modality (63% of drug-linked abstracts).","Acute kidney failure (AKF) was the most frequent disease (26%).","Genentech had the largest company share (8%).","Small molecules accounted for 63% of drug-linked abstracts, down from 66% in 2025.","Non-antibody therapeutic proteins accounted for 4% of drug-linked abstracts, down from 6% in 2025.",[217],{"year":218,"abstracts":219},2025,4399,{"previous_year":218,"abstracts":221,"targets":223,"modalities":229,"new_in_top_targets":238,"new_in_top_modalities":239},{"previous":219,"current":13,"change_pct":4,"direction":222},"fell",[224,227],{"name":23,"count":24,"share":25,"previous_count":225,"previous_share":106,"direction":226},70,"rose",{"name":35,"count":36,"share":33,"previous_count":228,"previous_share":19,"direction":222},59,[230,233,236],{"name":62,"count":63,"share":64,"previous_count":231,"previous_share":232,"direction":226},214,17,{"name":58,"count":59,"share":60,"previous_count":234,"previous_share":235,"direction":222},814,66,{"name":69,"count":70,"share":71,"previous_count":237,"previous_share":106,"direction":222},74,[48],[],[],1793970603086]